TransMedics Group, Inc. (TMDX) Stock Overview
Explore TransMedics Group, Inc.’s financial performance, market position, analyst ratings, and future outlook.
TransMedics Group, Inc. (TMDX)
Key Financials
Key Financials
Market Cap
3.1B
P/E Ratio
20.09
EPS (TTM)
$1.97
ROE
0.33%
TMDX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of TransMedics Group, Inc. (NASDAQ: TMDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, TransMedics Group, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TMDX on the NASDAQ shows an RSI of 68.05, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $113.94 for the NASDAQ listing.
Key metrics behind TransMedics Group, Inc.'s NASDAQ-traded stock include a P/E ratio of 20.09 and a market capitalization of 3.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TMDX on the NASDAQ.